ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 613

Correlation Between Efficacy of Tocilizumab and Levels of Oxidative Stress Markers in Patients with Rheumatoid Arthritis: the 52-Week Analysis

Hiroaki Niiro1, Hiroshi Tsukamoto2, Yojiro Arinobu2, Mitsuteru Akahoshi2, Hiroki Mitoma2, Kensuke Oryoji3, Yasushi Inoue4, Takuya Sawabe5, Shuji Nagano6, Hiroaki Nishizaka7, Seiji Yoshizawa8, Yoshifumi Tada9, Shigeru Yoshizawa10, Takeshi Otsuka11, Akira Ueda12, Hitoshi Nakashima13, Takahiko Horiuchi14 and Koichi Akashi2, 1Clinical Education Center, Kyushu University Hospital, Fukuoka, Japan, 2Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, 3The Center for Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan, 4Department of Rheumatology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan, 5Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan, 6Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, 7Kitakyushu Municipal Medical Center, Kitakyushu, Japan, 8Hamanomachi Hospital, Fukuoka, Japan, 9Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, 10Department of Rheumatology, Fukuoka Hospital, National Hospital Organization, Fukuoka, Japan, 11Munakata Medical Association Hospital, Munakata, Japan, 12Department of Internal Medicine, Miyazaki Prefectural Hospital, Miyazaki, Japan, 13Div of Nephrol & Rheumatol, Dept of Int Med, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, 14Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords:

Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Despite their profound inhibitory effects on inflammation and bone destruction, it remains unclear whether biological therapies can improve the long-term prognosis of patients with rheumatoid arthritis (RA). Enhanced risk of atherosclerotic cardiovascular (CV) disease is a key feature of RA. Oxidative stress is closely associated with the process of atherosclerosis. In the present study we have investigated the correlation between efficacy of 52-week treatment with tocilizumab (TCZ) and levels of oxidative stress markers in patients with RA.

Methods: Patients treated with TCZ were prospectively studied with informed consent. Efficacy of TCZ and levels of 8-OHdG and 8-iso-PGF2a in urine were evaluated by enzyme immunoassay and enzyme-linked immunosorbent assay, respectively, at baseline and 52 weeks.

Results: Thirty out of 82 patients with RA (mean age 61.0 years old; mean disease duration 7.5 years; concomitant MTX 60%) were studied at the 52-week analysis. The rate of DAS28 (ESR) and CDAI remission at 52 weeks was 76.7% and 33.3%, respectively. In all patients levels of 8-OHdG in urine were decreased (at baseline, 12.5 ng/mg Cr; at 6 months, 9.5 ng/mg Cr), while levels of 8-iso-PGF2a in urine were not altered (at baseline, 355.4 pg/mg Cr; at 6 months, 387.4 pg/mg Cr). Intriguingly, however, levels of  8-OHdG and 8-iso-PGF2a were both decreased in a subgroup of patients with RA who took concomitant MTX, at an early stage of disease, or achieved CDAI remission.  

Conclusion: Efficacy of 52-week treatment with TCZ correlated with reduced levels of oxidative stress markers in RA patients. This trend was noted in a subpopulation of patients with RA who took concomitant MTX, at an early stage of disease, or achieved CDAI remission.  Together, these findings suggest that treatment with TCZ improves the long-term prognosis of patients with RA by lowering the risk of CV events.

Disclosure: H. Niiro, None; H. Tsukamoto, None; Y. Arinobu, None; M. Akahoshi, None; H. Mitoma, None; K. Oryoji, None; Y. Inoue, None; T. Sawabe, None; S. Nagano, None; H. Nishizaka, None; S. Yoshizawa, None; Y. Tada, None; S. Yoshizawa, None; T. Otsuka, None; A. Ueda, None; H. Nakashima, None; T. Horiuchi, None; K. Akashi, None.

To cite this abstract in AMA style:

Niiro H, Tsukamoto H, Arinobu Y, Akahoshi M, Mitoma H, Oryoji K, Inoue Y, Sawabe T, Nagano S, Nishizaka H, Yoshizawa S, Tada Y, Yoshizawa S, Otsuka T, Ueda A, Nakashima H, Horiuchi T, Akashi K. Correlation Between Efficacy of Tocilizumab and Levels of Oxidative Stress Markers in Patients with Rheumatoid Arthritis: the 52-Week Analysis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/correlation-between-efficacy-of-tocilizumab-and-levels-of-oxidative-stress-markers-in-patients-with-rheumatoid-arthritis-the-52-week-analysis/. Accessed .

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/correlation-between-efficacy-of-tocilizumab-and-levels-of-oxidative-stress-markers-in-patients-with-rheumatoid-arthritis-the-52-week-analysis/